GeneQuine Biotherapeutics (Global Rights to GQ-203) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

GeneQuine Biotherapeutics (Global Rights to GQ-203) General Information

Description

A marketing rights of a gene therapy program. The program provides long-lasting pain relief and disease modification for Knee osteoarthritis.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • Harburger Schlossstr. 6-12
  • 21079 Hamburg
  • Germany
+49 040 000000000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

GeneQuine Biotherapeutics (Global Rights to GQ-203) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore GeneQuine Biotherapeutics (Global Rights to GQ-203)‘s full profile, request access.

Request a free trial

GeneQuine Biotherapeutics (Global Rights to GQ-203) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore GeneQuine Biotherapeutics (Global Rights to GQ-203)‘s full profile, request access.

Request a free trial